Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDCyclo Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 1 | -$0.19 | -$0.19 | -$0.19 |
| Q2 2025 | 1 | -$0.22 | -$0.22 | -$0.22 |
| Q3 2025 | 1 | -$0.21 | -$0.21 | -$0.21 |
| Q4 2025 | 1 | -$0.22 | -$0.22 | -$0.22 |
Cyclo Therapeutics, Inc. Earnings Date And Information
Cyclo Therapeutics, Inc. last posted its earnings results on Thursday, November 14th, 2024. The company reported $-0.26 earnings per share for the quarter, missing analysts' consensus estimates of $-0.17 by $0.09. The company had revenue of 233,772 for the quarter and had revenue of 1.08 M for the year. Cyclo Therapeutics, Inc. has generated $-1 earnings per share over the last year ($-1.23 diluted earnings per share) and currently has a price-to-earnings ratio of -0.78. Cyclo Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 17th, 2025 based on prior year's report dates.
Cyclo Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/13/2024 | Q3 2024 | -$0.17 | -$0.31 | -0.14 | $294,000 | $233,772 |
| 08/14/2024 | Q2 2024 | -$0.14 | -$0.21 | -0.07 | $267,500 | $123,104 |
| 05/15/2024 | Q1 2024 | -$0.20 | -$0.15 | 0.05 | N/A | $202,450 |
| 04/29/2024 | Q4 2023 | N/A | -$0.23 | N/A | N/A | $311,399 |
| 11/14/2023 | Q3 2023 | -$0.27 | -$0.29 | -0.02 | $141,000 | $495,477 |
| 08/14/2023 | Q2 2023 | N/A | -$0.33 | N/A | $183,000 | $117,118 |
| 05/12/2023 | Q1 2023 | N/A | -$0.46 | N/A | N/A | $152,411 |
| 05/01/2023 | Q4 2022 | N/A | -$0.57 | N/A | N/A | $186,803 |
| 11/10/2022 | Q3 2022 | N/A | -$0.50 | N/A | $618,000 | $452,167 |
| 08/15/2022 | Q2 2022 | N/A | -$0.41 | N/A | $571,000 | $541,886 |
| 05/12/2022 | Q1 2022 | -$0.48 | $19,361.00 | 19361.48 | N/A | $194,904 |
| 03/11/2022 | Q4 2021 | N/A | -$0.43 | N/A | N/A | $585,115 |
| 11/15/2021 | Q3 2021 | -$0.67 | -$0.60 | 0.07 | $382,000 | $403,918 |
| 08/16/2021 | Q2 2021 | N/A | -$0.56 | N/A | $360,000 | $238,590 |
| 05/14/2021 | Q1 2021 | N/A | -$0.76 | N/A | N/A | $358,133 |
| 03/12/2021 | Q4 2020 | N/A | -$0.50 | N/A | N/A | $145,586 |
| 11/12/2020 | Q3 2020 | N/A | -$0.85 | N/A | N/A | $222,462 |
| 08/14/2020 | Q2 2020 | N/A | -$1.60 | N/A | N/A | $209,594 |
| 05/15/2020 | Q1 2020 | N/A | -$2.17 | N/A | N/A | $325,734 |
| 03/30/2020 | Q4 2019 | -$1.00 | -$2.20 | -1.2 | N/A | $227,363 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Cyclo Therapeutics, Inc. Earnings: FAQ's
Cyclo Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 17th, 2025 based offlast year's report dates.
The conference call for Cyclo Therapeutics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Cyclo Therapeutics, Inc.'s latest earnings report can be read online.
Cyclo Therapeutics, Inc. (:CYTH) has a recorded annual revenue of $1.08 M.
Cyclo Therapeutics, Inc. (:CYTH) has a recorded net income of $-20,057,302.Cyclo Therapeutics, Inc. has generated $-1.23 earnings per share over the last four quarters.
Cyclo Therapeutics, Inc. (:CYTH) has a price-to-earnings ratio of -0.78 and price/earnings-to-growth ratio is 0.34.